Acumen Pharmaceuticals (ABOS) Long-Term Investments (2021 - 2025)

Acumen Pharmaceuticals' Long-Term Investments history runs 5 years deep, the most recent figure standing at $9.4 million for Q3 2025.

• In Q3 2025, Long-Term Investments fell 83.87% year-over-year to $9.4 million; the TTM figure through Sep 2025 stood at $9.4 million (down 83.87% YoY), while the FY2024 annual figure was $60.0 million, down 4.13% from the prior year.
• Long-Term Investments came in at $9.4 million for Q3 2025 at Acumen Pharmaceuticals, down from $22.8 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $67.3 million in Q3 2023 to a low of $9.4 million in Q3 2025.
• A 5-year average of $36.9 million and a median of $30.8 million in 2021 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments soared 294.98% in 2023 and plunged 83.87% in 2025, its largest moves.
• Acumen Pharmaceuticals' Long-Term Investments stood at $31.6 million in 2021, then slumped by 49.91% to $15.8 million in 2022, then jumped by 294.98% to $62.6 million in 2023, then declined by 4.13% to $60.0 million in 2024, then tumbled by 84.25% to $9.4 million in 2025.
• According to Business Quant data, Long-Term Investments over the past three periods registered $9.4 million, $22.8 million, and $48.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.

Peer Comparison